TGM2 and chronic kidney disease: Using an in vivo CKD model, two different irreversible inhibitors of TG2 prevented a decline in kidney function and reduced the development of glomerulosclerosis and tubulointerstitial fibrosis by up to 77% and 92%, respectively [18,19].